

Claudia De Lorenzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5360932/publications.pdf>

Version: 2024-02-01

69
papers

1,924
citations

172386
29
h-index

289141
40
g-index

69
all docs

69
docs citations

69
times ranked

2039
citing authors

#	ARTICLE	IF	CITATIONS
1	A Study of the Intracellular Routing of Cytotoxic Ribonucleases. <i>Journal of Biological Chemistry</i> , 1995, 270, 17476-17481.	1.6	86
2	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , 2012, 14, 130-137.	2.9	77
3	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 358-366.	2.9	76
4	The antitumor action of seminal ribonuclease and its quaternary conformations. <i>FEBS Letters</i> , 1995, 359, 31-34.	1.3	71
5	A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas. <i>Cancer Research</i> , 2004, 64, 4870-4874.	0.4	67
6	A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7768-7773.	3.3	66
7	Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. <i>FASEB Journal</i> , 2009, 23, 3171-3178.	0.2	63
8	The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. <i>Oncogene</i> , 2001, 20, 599-608.	2.6	57
9	Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 595-602.	1.1	56
10	Human anti-nucleolin recombinant immunoagent for cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 9418-9423.	3.3	53
11	Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e19-e26.	0.6	47
12	Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1124-1131.	1.4	46
13	A new human antitumor immunoreagent specific for ErbB2. <i>Clinical Cancer Research</i> , 2002, 8, 1710-9.	3.2	46
14	Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling. <i>Scientific Reports</i> , 2019, 9, 13125.	1.6	44
15	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179.	0.8	44
16	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 511-521.	1.1	43
17	A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. <i>British Journal of Cancer</i> , 2004, 91, 1200-1204.	2.9	41
18	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179.	1.1	41

#	ARTICLE	IF	CITATIONS
19	Effects of Protein RNase Inhibitor and Substrate on the Quaternary Structures of Bovine Seminal RNase. <i>Biochemistry</i> , 1996, 35, 3880-3885.	1.2	39
20	Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing. <i>Cancers</i> , 2019, 11, 1268.	1.7	38
21	Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 180.	3.5	38
22	From ImmunoToxins to ImmunoRNases. <i>Current Pharmaceutical Biotechnology</i> , 2008, 9, 210-214.	0.9	38
23	Biological properties of a human compact anti-ErbB2 antibody. <i>Carcinogenesis</i> , 2005, 26, 1890-1895.	1.3	37
24	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , 2018, 9, 38.	1.3	36
25	A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. <i>British Journal of Cancer</i> , 2011, 104, 1716-1723.	2.9	35
26	Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. <i>FEBS Journal</i> , 2008, 275, 4967-4979.	2.2	33
27	A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. <i>FEBS Letters</i> , 2002, 516, 208-212.	1.3	32
28	Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. <i>FEBS Letters</i> , 2007, 581, 296-300.	1.3	31
29	Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. <i>MAbs</i> , 2018, 10, 1-13.	2.6	31
30	Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. <i>British Journal of Cancer</i> , 2010, 102, 513-519.	2.9	29
31	Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. <i>Cancers</i> , 2020, 12, 331.	1.7	27
32	Long-chain polyphosphates impair SARS-CoV-2 infection and replication. <i>Science Signaling</i> , 2021, 14, .	1.6	27
33	Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2241-2250.	1.0	26
34	Crystal structure of the dimeric unswapped form of bovine seminal ribonuclease. <i>FEBS Letters</i> , 2003, 554, 105-110.	1.3	25
35	A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells. <i>MAbs</i> , 2018, 10, 730-737.	2.6	25
36	Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6785-6794.	1.0	24

#	ARTICLE	IF	CITATIONS
37	A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. <i>Oncotarget</i> , 2016, 7, 87016-87030.	0.8	23
38	Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8562.	1.8	20
39	Human anti-ErbB2 immunoagents as immunoRNases and compact antibodies. <i>FEBS Journal</i> , 2009, 276, 1527-1535.	2.2	19
40	A novel fully human antitumor ImmunRNase resistant to the RNase inhibitor. <i>Protein Engineering, Design and Selection</i> , 2013, 26, 243-248.	1.0	17
41	Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. <i>Journal of Biological Chemistry</i> , 2014, 289, 35015-35028.	1.6	17
42	Effects of a second-generation human anti-ErbB2 ImmunRNase on trastuzumab-resistant tumors and cardiac cells. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 83-88.	1.0	16
43	One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	16
44	Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. <i>Journal of General Virology</i> , 2016, 97, 82-94.	1.3	16
45	High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand. <i>Cancers</i> , 2022, 14, 1325.	1.7	14
46	A Novel Human Antitumor Dimeric ImmunRNase. <i>Journal of Immunotherapy</i> , 2008, 31, 440-445.	1.2	13
47	Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 11046.	1.6	13
48	A novel ErbB2 epitope targeted by human antitumor immunoagents. <i>FEBS Journal</i> , 2011, 278, 1156-1166.	2.2	12
49	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020, 12, 2204.	1.7	12
50	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021, 13, 2858.	1.7	12
51	Thermodynamic Stability of the Two Isoforms of Bovine Seminal Ribonuclease. <i>Biochemistry</i> , 2000, 39, 7964-7972.	1.2	11
52	Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. <i>British Journal of Cancer</i> , 2007, 97, 1354-1360.	2.9	11
53	T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. <i>Journal of Immunotherapy</i> , 2019, 42, 1-10.	1.2	11
54	Trypsin Sheds Light on the Singular Case of Seminal RNase, a Dimer with Two Quaternary Conformations. <i>Journal of Biological Chemistry</i> , 2000, 275, 8000-8006.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Crystallization of multiple forms of bovine seminal ribonuclease in the liganded and unliganded state. <i>Journal of Crystal Growth</i> , 1999, 196, 305-312.	0.7	9
56	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019, 2019, 1-22.	0.9	9
57	Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
58	Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody. <i>Journal of Immunotherapy</i> , 2017, 40, 117-128.	1.2	7
59	Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC. <i>Cancers</i> , 2022, 14, 121.	1.7	7
60	Selective and asymmetric action of trypsin on the dimeric forms of seminal RNase. <i>Protein Science</i> , 1998, 7, 2653-2658.	3.1	6
61	Effects of a human compact anti-ErbB2 antibody on gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 107-115.	2.7	6
62	Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3466.	1.8	6
63	Effects of a human compact anti-ErbB2 antibody on prostate cancer. <i>Oncology Reports</i> , 2012, 28, 297-302.	1.2	3
64	A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5556.	1.8	3
65	A Practical Approach for Management of QT Prolongation Induced by Anticancer Drugs. <i>Oncologist</i> , 2016, , .	1.9	1
66	Ranolazine and prevention of trastuzumab-cardiotoxicity in experimental models.. <i>Journal of Clinical Oncology</i> , 2014, 32, e13508-e13508.	0.8	0
67	Effect of ranolazine administered after trastuzumab treatment on cardiotoxicity in mice.. <i>Journal of Clinical Oncology</i> , 2015, 33, 597-597.	0.8	0
68	Differential cardiotoxicity of immune checkpoint inhibitors involves dampens fibronectin-EDA, calgranulin, galectine-3, and associated nlrp3 inflammasome-interleukins pathway in preclinical models. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
69	Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, Galectine-3 and NLRP3-MyD88-chemokine pathways.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14516-e14516.	0.8	0